A second possible mechanism of action is that IPO13 variants improve airway hyperresponsiveness by enhancing the local anti-inflammatory effects of circulating, endogenous GCs by facilitating increased GR transport into the nucleus and thus increasing the effective bioavailability of endogenous GC. The gene discussed is NR3C1; the disease is airway hyperresponsiveness.